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Epstein–Barr virus (EBV) is a human γ-herpesvirus that establishes latency and lifelong 
infection in host B cells while achieving a balance with the host immune response. When 
the immune system is perturbed through immunosuppression or immunodeficiency, 
however, these latently infected B cells can give rise to aggressive B cell lymphomas. 
Natural killer (NK) cells are regarded as critical in the early immune response to viral 
infection, but their role in controlling expansion of infected B cells is not understood. 
Here, we report that NK cells from healthy human donors display increased killing of 
autologous B lymphoblastoid cell lines (LCLs) harboring latent EBV compared to pri-
mary B cells. Coculture of NK cells with autologous EBV+ LCL identifies an NK cell 
population that produces IFNγ and mobilizes the cytotoxic granule protein CD107a. 
Multi-parameter flow cytometry and Boolean analysis reveal that these functional cells 
are enriched for expression of the NK cell receptor NKG2A. Further, NKG2A+ NK cells 
more efficiently lyse autologous LCL than do NKG2A− NK cells. More specifically, 
NKG2A+2B4+CD16−CD57−NKG2C−NKG2D+ cells constitute the predominant NK cell 
population that responds to latently infected autologous EBV+ B cells. Thus, a subset of 
NK cells is enhanced for the ability to recognize and eliminate autologous, EBV-infected 
transformed cells, laying the groundwork for harnessing this subset for therapeutic use 
in EBV+ malignancies.
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inTrODUcTiOn
Epstein–Barr virus (EBV) is a ubiquitous γ-herpesvirus that persists as a chronic, asymptomatic 
infection in over 90% of the adult human population (1). EBV preferentially establishes infection in 
naïve tonsillar B cells. EBV remains in the lytic phase of infection in a minority of cells, producing 
infectious viral particles that are spread by oral transmission. Latent infection is established in the 
vast majority of infected cells and is responsible for driving infected B cells into the memory B cell 
reservoir, where the virus persists for the lifetime of the host; in healthy carriers, an average of 10 of 
every million peripheral blood memory B cells are EBV-infected (1, 2). Distinct viral proteins from 
both lytic and latent cycles of infection elicit a robust cellular immune response in the host.
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While the T cell response to EBV-infected cells has been 
extensively studied (3), several lines of evidence from murine 
models and human studies suggest that natural killer (NK) cells 
are also critical in host immunity to EBV. First, in humanized 
murine models, depletion of NK cells increases features typical of 
infectious mononucleosis (IM) (4) and promotes EBV-associated 
tumorigenesis (4, 5). Second, human NK cells kill lytically 
infected allogeneic B cells in  vitro (6, 7). Third, NK cell num-
bers expand during primary symptomatic EBV infection in IM 
patients (8, 9). Finally, patients with X-linked lymphoproliferative 
syndrome and X-linked immunodeficiency with Mg2+ defect, 
EBV infection, and neoplasia (XMEN) have NK deficiencies 
and suffer from life-threatening complications of EBV infection 
including IM and spontaneous EBV-associated malignancies 
(10–18). Notably, these complications appear to be related to NK 
cell function because they often occur in the presence of normal 
CD8+ T cell responses and involve defective NK receptor (NKR) 
expression or signaling (13–18).
Natural killer cells are phenotypically heterogeneous in 
their expression of inhibitory and activating NKRs (19). 
Inhibitory receptors include NKG2A and many of the killer 
immunoglobulin-like receptors (KIR), while activating NKRs 
include NKG2D, NKG2C, and the natural cytotoxicity recep-
tors. Subsets of NK cells defined by their NKR expression 
have been described in response to specific pathogens. For 
example, NKG2C+ NK cells preferentially expand during acute 
human cytomegalovirus (CMV) infection as well as in CMV-
seropositive individuals co-infected with hantavirus, chikun-
gunya virus, chronic HIV, or chronic hepatitis B or C (20–26). 
Along similar lines, recent evidence suggests that particular 
NK cell subsets respond to EBV infection. For instance, a 
IFNγhiCD56brightNKG2A+CD94+CD54+CD62L− NK cell subset 
accumulates in the tonsils of EBV carriers and reduces B cell 
transformation by EBV more potently than other CD56bright 
NK cells (27). Further, CD56dimKIR−NKG2A+ NK cells pref-
erentially proliferate during acute EBV+ IM and degranulate 
in response to allogeneic B cells displaying EBV lytic antigens 
(7). Finally, a mature CD56dimNKG2A+CD57+ NK population 
persists after acute EBV infection in individuals co-infected 
with CMV (28).
Thus, various NKR and NK cell subsets have been implicated 
in the primary response to EBV-infected cells during acute IM 
and B cell transformation by EBV. However, latent infection 
dominates the landscape of EBV. Failure to control latent EBV 
infection can lead to serious disease, particularly from a variety of 
EBV-associated malignancies, including lymphoproliferative dis-
eases (EBV-LPD). EBV-LPD represent a spectrum of potentially 
fatal lymphoproliferations, often involving B lymphocytes, which 
arise when the immune system is compromised by posttransplant 
immunosuppression, HIV, immunomodulating biologicals, 
or advancing age (29–32). The role of NK cells in the immune 
response to autologous cells latently infected with EBV is unclear. 
Thus, our goal was to assess the ability of NK cells to recognize 
and respond to autologous lymphoblastoid cell lines (LCLs), in 
order to better understand mechanisms that prevent expansion 
of latently infected cells in healthy individuals and to present new 
therapeutic opportunities for EBV-LPD.
MaTerials anD MeThODs
lcl generation, Primary B cell and nK 
cell isolation, and cell lines
EBV+ LCLs were generated from 11 healthy donors by infection 
of freshly isolated PBMCs with the B95.8 laboratory strain of 
EBV, as previously described (33). LCL and the MHC-Ilo 721.221 
cell line were maintained in RPMI (Corning) supplemented 
with 10% FBS (Serum Source International) and 1% penicillin/
streptomycin (Corning) [complete RPMI (cRPMI)]. Primary NK 
cells or B cells were negatively selected from whole blood using 
the RosetteSep Human NK Enrichment Kit or Human B Cell 
Enrichment Kit, respectively (Stem Cell Technologies). Purity 
was routinely (90% (Figures S1A,B in Supplementary Material). 
Purified primary NK cells were cultured for 2 days in cRPMI sup-
plemented with 300 U/mL IL-2 (NIH Reagent Program) prior to 
stimulation or coculture. This study was performed in accordance 
with the Declaration of Helsinki and approved by the Stanford 
University Institutional Review Board, and written informed 
consent was obtained from all participants.
cytotoxicity assay
Natural killer cell cytotoxicity was assayed by a modified ACT1 
assay (Cell Technology). Briefly, target cells (721.221, primary 
B cells, autologous LCL) were incubated with 0.25 µM CFSE in 
PBS + 2.5% FBS for 5 min at room temperature, then washed 
twice with 10 volumes cRPMI. A total of 0.5 × 105 target cells 
were cocultured for 4 h in a 37°C-5% CO2 humidified incubator 
with 2 × 105 NK cells, for a final ratio of 4 NK cells:1 target cell. 
Cocultures were pelleted, resuspended in 200  µL cRPMI, and 
incubated with 5 µL 7-aminoactinomycin D (7-AAD) for 15 min 
on ice. Unlabeled target cells served as a control for gating, while 
CFSE-labeled target cells treated with 1× final FACS Perm (BD 
Pharmingen) for the final 15 min of the coculture served as a 
positive control for maximum target cell death. Cells were ana-
lyzed on a FACScan flow cytometer with CellQuest Software, 
and dead target cells were identified as CFSE+7-AAD+. Specific 
killing was calculated as [(%CFSE+7-AAD+NK:Target − % CFSE+7-
AAD+Target Only)/(%  CFSE+7-AAD+Permeabilized Target  − %  CFSE+7- 
AAD+Target Only)] × 100.
For the cytotoxicity assay using purified NKG2A+ and NKG2A− 
NK cells, NK cells were isolated using an NK Isolation Kit (Miltenyi) 
and cultured in RPMI complete with 300 U/ml IL-2 for 2 days. 
NK cells were then stained with NKG2A-PE (Beckman Coulter, 
clone Z199), CD3-APC (Biolegend), CD56-PE Cy7 (Biolegend), 
CD16-PerCP Cy5.5 (Biolegend), and Fixable Viability Dye eFluor 
780 (eBioscience) and sorted for live CD3−CD56+CD16+ and 
NKG2A± on a BD FACSAria. Sorted cells were rested in RPMI 
complete with 300 U/ml IL-2 for 2 h at 37°C before the start of 
the killing assay. LCLs were labeled with 0.5 µM CellTrace Violet 
(Invitrogen) for 20 min at 37°C, then washed twice with at least 
10 volumes of RPMI complete. LCL target cells (2.5 × 104) were 
cocultured with 1 ×  105 sorted NKG2A+ or NKG2A− NK cells 
for 4 h in a 37°C incubator for a 4:1 E:T ratio. At the end of the 
coculture, cells were stained for viability using Fixable Viability 
Dye eFluor 780 (eBioscience) at the manufacturer’s recommended 
3Hatton et al. NKG2A Defines EBV-Responsive NK Cells
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 607
concentration, for 10 min on ice. Cells were then washed twice 
with PBS before analysis as above.
analysis of nK ligand expression
PBMCs were isolated from whole blood by Ficoll-Paque (GE 
Healthcare). PBMC and LCL were stained with the following 
antibodies or matched isotype controls: anti-CD48-PE, anti-
CD19-FITC, anti-CD19-PE, anti-HLA-E-PE, and anti-HLA-
A,B,C-FITC (BD Pharmingen) and analyzed by flow cytometry. 
All antibodies were titrated on positive control cell lines; these 
lines were stained as a positive control in each experiment. Stain 
indexes were used to compare NK ligand expression on CD19+-
gated primary B cells and autologous LCL (34). Stain indexes 
were calculated using the mean fluorescence intensities (MFI) as 
(MFIligand − MFIisotype)/(2 × SDisotype).
nK:Target cell cocultures and  
Flow cytometric analysis
IL-2 primed NK cells (0.25 × 106 cells/condition) were cocultured 
with equal amounts of 721.221, primary B cells, or autologous 
LCL in 200  µL final volume (Figure S2A in Supplementary 
Material). NK cells were left unstimulated (NK only) as a nega-
tive control or were stimulated with 1× PMA/Ionomycin Cell 
Stimulation Cocktail (eBioscience) as a positive control. All 
cells were cultured in cRPMI supplemented with 300  U/mL 
IL-2, 1× final brefeldin A/monensin protein transport inhibitor 
(eBioscience), and anti-CD107a-Pacific blue (BioLegend). After 
4 h incubation in a 37 C-5% CO2 humidified incubator, 1.8 mM 
EDTA was added for 5  min to arrest stimulation. Cells were 
stained with the near IR Live/Dead stain (Life Technologies), 
washed, and then stained with anti-CD3-Alexa 700, anti-CD14-
Alexa 700, anti-CD19-Alexa 700, anti-CD56-Brilliant Violet 
605, anti-NKG2D-PE,Cy7, anti-2B4-PerCP,Cy5.5 (BioLegend), 
anti-CD16-V500 (BD Pharmingen), anti-NKG2C-PE (R&D 
Systems), and anti-NKG2A-FITC (Miltenyi). Cells were then 
fixed and permeabilized with FACS Lyse and FACS Perm II (BD 
Pharmingen), according to the manufacturer’s instructions. Cells 
were then stained with anti-IFNγ-Brilliant Violet 785. All anti-
bodies were titrated on PBMC prior to use. Fluorescence minus 
one-stained PBMC were run for each experiment and used to set 
gates for each parameter. Data were collected on a four-laser LSRII 
with FACS DiVA software at the Stanford Shared FACS Facility.
Data and statistical analysis
Flow cytometry data were analyzed using FlowJo, version 9.7.6 
(Tree Star). Statistical analysis was performed using Prism, ver-
sion 6.0d (GraphPad Software). All paired data were compared 
using the Wilcoxon matched-pairs signed rank test. A Bonferroni 
correction was used to adjust for multiple comparisons.
resUlTs
expression of nK cell receptor  
ligands on eBV+ lcl
Lymphoblastoid cell lines are CD19+ EBV-transformed B 
cell lines which display a viral latency type III pattern of 
gene expression and resemble EBV-LPDs like posttransplant 
lymphoproliferative disorder (35). We, therefore, analyzed 
expression of NKR ligands on LCL to evaluate how these cells, 
as a model of predominantly latent infection, stimulate NK cell 
recognition. We compared NK cell ligand staining on EBV+ 
LCL with primary autologous CD19+ B cells (Figure 1; Figure 
S1A in Supplementary Material). To account for the increased 
autofluorescence of EBV+ LCL, we used the stain index (34) 
to normalize expression levels to the corresponding isotype 
staining (Figures  1A–F). After normalization, EBV+ LCL 
(n =  6) display increased expression of the 2B4 ligand CD48 
[Figures 1A,D (36)], lower expression of the inhibitory ligand 
MHC class I (HLA-A,B,C; Figures  1B,E), and no significant 
difference in expression of the NKG2A and NKG2C ligand 
HLA-E (Figures  1C,F) compared to autologous, primary 
CD19+ B cells.
nK cells Kill autologous eBV+ lcl
We next tested the ability of purified NK cells to kill autologous 
EBV+ LCL using a flow cytometry-based cytotoxicity assay 
(Figures S1B,C in Supplementary Material; Figure  1G). NK 
cells robustly kill the MHC-Ilo positive control cell line 721.221 
target (87.1 ±  3.7% SEM, Figure  1H). NK cells from healthy 
donors (n =  7) display significantly more cytotoxicity against 
autologous EBV+ LCL than against primary unstimulated B cells 
(8 ± 2.1% SEM versus 2.8 ± 0.6% SEM, p = 0.016; Figure 1H). 
The NK cytotoxicity against autologous EBV+ LCL is likely 
predominantly directed at latently infected LCL, because less 
than 2% of EBV+ LCL express the lytic antigen BZLF1 (Figure 
S3 in Supplementary Material) (6). Thus, transformed B cells 
harboring a latent EBV infection can elicit a cytotoxic response 
by autologous NK cells.
To evaluate the NK cell activity during the targeting of autolo-
gous EBV-infected LCL, cocultures were stained with a panel of 
antibodies to identify NK cell subsets and their function (Figure 
S2A in Supplementary Material). NK cells (defined as CD3+ 
CD14+CD19+CD56+ live singlets, Figure S2B in Supplementary 
Material) capable of releasing cytotoxic granules and/or produc-
ing cytokines were identified by staining for CD107a mobilization 
and intracellular IFNγ, respectively. In response to the positive 
control cell line 721.221, 20 ±  2% SEM of NK cells produce 
IFNγ, 29 ± 2% SEM of NK cells degranulate, and 17 ± 2% SEM 
of NK cells both degranulate and produce IFNγ above NK only 
background (Figure  2). In response to the autologous EBV+ 
LCL, 4.1 ± 2% SEM of NK cells produce IFNγ, 13.5 ± 6% SEM 
degranulate, and 2.6 ± 1.2% SEM of NK cells both degranulate 
and produce IFNγ above NK only background levels in NK only 
conditions (Figure 2). Thus, a small population of NK cells can 
respond to autologous EBV+ LCL.
nKg2a expression Defines a subset  
of nK cells enriched in the ability to 
respond to autologous eBV+ lcl
To identify markers that can distinguish NK cells that respond to 
EBV+ LCL, we examined expression of the activating receptors 
FigUre 1 | nK cells kill autologous eBV+ lcl. (a–F) Expression of NK ligands CD48, HLA-A,B,C, and HLA-E on autologous CD19+ B cells and EBV+ LCL. 
(a–c) Representative flow cytometry shows isotype (light gray shaded) or NK ligand-stained (light gray outline) primary CD19+ B cells or isotype (dark gray shaded) 
or NK ligand-stained (dark gray outline) autologous LCLs. (D–F) Stain indices (34) of N = 6 donors. (g) NK killing of CFSE-labeled target cells (721.221, primary 
B cells and autologous LCL target cells). The percentage of dead target cells, as detected by 7-AAD and CFSE, are shown in representative samples. (h) Specific 
killing was calculated as described in Section “Materials and Methods.” Each of the N = 7 donors is labeled with a unique symbol. Error bars represent the minimum 
and maximum values for each condition. All p-values were calculated using the Wilcoxon matched-pairs signed rank test.
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CD16, 2B4, NKG2C, and NKG2D, the inhibitory receptor NKG2A, 
and the maturity marker CD57 on NK cells that had produced 
IFNγ and/or degranulated after coculture with autologous EBV+ 
LCL. Within an individual, each marker is expressed on a sub-
set of total NK cells (Figure S4A in Supplementary Material). 
Expression of NK cell markers also varied among individuals. 
FigUre 3 | higher frequencies of nK cells responding to autologous 
lcl are nKg2a+. Frequency of 2B4+, CD16+, CD57+, NKG2A+, NKG2C+, 
and NKG2D+ cells within IFNγ− or IFNγ+ (a), CD107a− or CD107a+ (B), and 
CD107a−IFNγ+ or CD107a+IFNγ+ (c) NK populations after coculture with 
autologous LCL (N = 10). All p-values were calculated using the Wilcoxon 
matched-pairs signed rank test.
FigUre 2 | nK cells respond to autologous lcl and primary B cells 
with similar frequency. IFNγ (a), CD107a (B), or both (c) expression on 
NK cells (CD3−CD14−CD19−CD56+) alone (NK only) or after coculture with 
target cells (721.221 cells, primary B cells, or autologous LCLs). Error bars 
represent the minimum and maximum values for each condition. Each of the 
N = 10 donors is labeled with a unique symbol. All p-values were calculated 
using the Wilcoxon matched-pairs signed rank test.
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For example, the frequency of NKG2A+ cells in the total NK 
population ranges from 23.6–76.3%, in line with other published 
data (19, 37). Responding (IFNγ+ and/or CD107a+) NK cells 
are far less likely to express CD16 than non-responding (IFNγ+ 
and/or CD107a−) NK cells (Figure 3), consistent with the fact 
that CD16 expression is downregulated upon NK cell activation 
(38, 39). There are no significant differences in the frequencies 
of responding versus non-responding NK cells that were 2B4+, 
CD57+, NKG2C+, or NKG2D+ (Figure 3). In contrast, the fre-
quency of NK cells mounting a functional response to autologous 
EBV+ LCL is significantly enriched for expression of NKG2A 
compared to NK cells that do not mount a functional response 
(Figure 3).
To determine whether the population of NK cells that 
respond to EBV+ LCL is distinct from those that respond to 
uninfected B cells, we compared the expression of the markers 
CD16, CD57, 2B4, NKG2A, NKG2C, and NKG2D on NK cells 
responding to autologous EBV+ LCL versus primary B cells. 
There are no significant differences in the frequency of NK cells 
expressing CD16 in NK cells responding to primary B cells versus 
autologous EBV+ LCL (Figure 4). In contrast, the population of 
NK cells responding to autologous, EBV+ LCLs contains sig-
nificantly higher frequencies of NKG2A+ cells than the NK cells 
responding to primary B cells (Figure 4). Moreover, the propor-
tion of NKG2C+ cells in the subset of CD107a+IFNγ+ NK cells 
that respond to autologous EBV+ LCL is reduced (Figure 4C). 
FigUre 5 | higher frequencies of nK cells responding specifically to autologous lcl are nKg2a+2B4+cD16−cD57−nKg2c−nKg2D+.
FigUre 4 | higher frequencies of nK cells respond specifically to autologous lcl and not primary B cells are nKg2a+. Frequency of CD16+, NKG2A+, 
and NKG2C+ cells within IFNγ+ (a), CD107a+ (B), and CD107a+IFNγ+ (c) NK populations after coculture with primary B cells (open circles) or autologous LCL (filled 
circles) from N = 10 donors. All p-values were calculated using the Wilcoxon matched-pairs signed rank test.
(Continued)
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FigUre 5 | continued  
Visualization of the frequencies of 64 different NK receptor combinations in each of N = 10 donors within CD107a+IFNγ+ NK populations cocultured with primary 
B cells (a) and autologous LCL (B). The 11 most frequent receptor combinations are shown in color, and the legend describes these combinations of 2B4 (2B), 
CD16 (16), CD57 (57), NKG2A (2A), NKG2C (2C), and NKG2D (2D). (c) The average difference in each receptor combination between CD107a+IFNγ+ NK cells from 
cocultures with primary B cells or autologous LCLs and (D–n) comparisons of the frequencies between CD107a+IFNγ+ NK populations from coculture with primary 
B cells (open circles) and autologous LCL (filled circles). All p-values were calculated using the Wilcoxon matched-pairs signed rank test. A Bonferroni correction 
was used to adjust for multiple comparisons.
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There  are no significant differences in the percentage of 2B4+, 
CD57+, or NKG2D+ NK cells responding to autologous EBV+ 
LCLs versus primary B cells (Figure S4 in Supplementary 
Material). Together, these data suggest that expression of NKG2A 
can distinguish a subset of NK cells that can specifically respond 
to B cells displaying latent EBV infection.
To further characterize the NK cell subsets responding to 
latent EBV+ LCL, we examined the NK cell response to EBV 
using combinations of the six NKRs 2B4, CD16, CD57, NKG2A, 
NKG2C, and NKG2D. Using a Boolean approach, we determined 
the frequency of each of the 64 potential NK cell subsets defined 
by expression of the six NK cell receptors on NK cells respond-
ing, on the basis of CD107a and/or IFNγ expression, to coculture 
with primary B cells or autologous LCL (shown for each donor in 
Figures 5A,B, respectively). To identify EBV-responsive NK cell 
subsets, we normalized the frequency of NK cells responding to 
autologous LCL to the frequency responding to primary B cells. 
The average normalized percentage of each of these subsets 
among the 10 donors is displayed in Figure 5C. This analysis sug-
gests that the NKG2A+2B4+CD16−CD57−NKG2C−NKG2D+ NK 
cell population is the most responsive against EBV-infected LCL, 
as it was consistently more responsive to autologous LCL than to 
primary B cells, though this effect was not statistically significant 
after controlling for multiple comparisons (Figures  5D–N). 
Consistent with these observations, the diversity of the respond-
ing cells (CD107a+IFNγ+) was lower in 8 of 10 donors cocultured 
with autologous LCL compared to primary B cells (Figure S5 in 
Supplementary Material); this reduced diversity also suggests that 
the specific response to EBV infection may be driven by a subset 
of EBV-responsive NK cells. Together, these data suggest that a 
FigUre 6 | nKg2a+ nK cells kill autologous lcl better than nKg2a− 
nK cells. NKG2A+ and NKG2A− NK cells were sorted and placed in a killing 
assay with CellTrace Violet-labeled autologous LCL targets at a 4:1 
effector:target ratio. Specific killing was calculated as described in Section 
“Materials and Methods.” Each of the N = 6 donors is labeled with a unique 
symbol. All p-values were calculated using the Wilcoxon matched-pairs 
signed rank test.
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subset of NK cells, identified as NKG2A+2B4+CD16−CD57−NK
G2C−NKG2D+, can respond specifically to EBV+ LCL.
To better define the NK cell subset responding to autologous 
LCL, we evaluated NK cell IFNγ secretion and CD107a activ-
ity in the presence of antibodies that were previously reported 
to block NKG2D, NKG2A, and 2B4. Blocking NKG2D led to a 
consistent decrease in the frequency of NK cells producing IFNγ 
and CD107a, but the effects of NKG2A and 2B4 blocking were 
less dramatic, in some cases enhancing activity (Figure S6 in 
Supplementary Material). This implies that NKG2D is involved in 
the recognition of autologous LCL, but cannot explain the entire 
effect. As NKG2A is an inhibitory receptor, it is likely that it may 
not be directly involved in killing but instead may mark a respon-
sive subset. Thus, to confirm the role of NKG2A-expressing NK 
cells in the response to autologous EBV+ LCL, we compared the 
ability of NKG2A+ and NKG2A− NK cells from the same donor 
for their ability to kill autologous EBV+ LCL. In all six donors, 
NKG2A+ NK cells display higher killing than did NKG2A− NK 
cells (Figure 6; Figure S7 in Supplementary Material, p = 0.03), 
confirming that NK cell subsets that are functionally responsive 
to EBV+ LCL are enriched for NKG2A expression.
DiscUssiOn
Latent infection dominates the EBV life cycle, and failure to 
adequately control latent EBV infection has serious consequences 
including the development of a spectrum of EBV-LPD. NK cells 
represent previously under-appreciated players in the immune 
response to EBV infection. Here, we demonstrate that NK cells 
display cytotoxicity specifically against autologous EBV+ LCL. 
Compared to host B cells, autologous EBV+ LCL upregulate 
expression of the NK activating ligand CD48 and reduce expres-
sion of the NK inhibitory ligand MHC class I, potentially making 
them targets of NK cell-mediated lysis. Consistent with this 
observation, we find that NKG2A-expressing NK cells are par-
ticularly enriched for the ability to respond to autologous EBV+ 
LCL. Thus, while prior studies highlighted the ability of NK cells 
to distinguish active, lytic infection (4, 7, 27), our data indicate 
that NK cells are capable of distinguishing autologous EBV+ 
LCL from healthy B cells, potentially laying the groundwork for 
harnessing their activity in the treatment of EBV-LPD.
The majority of studies on the NK cell response to EBV have 
focused on NK cells during primary infection or upon lytic 
reactivation of the virus. NK cell activity has been shown to be 
greater against lytically infected targets than against the corre-
sponding latently infected targets (6, 7). However, these studies 
used the allogeneic Akata target cell lines, raising the possibility 
that “missing self ” targeting by NK cells could have contributed 
to the activity observed. Our data demonstrating that NKG2A-
expressing NK cells predominate in the NK response to latently 
infected LCL represents a clinically relevant autologous interac-
tion given that latency is the major phase of the EBV life cycle. 
Our analysis takes into account any relevant non-specific activity 
against uninfected host B cells, allowing us to identify the subset of 
NK cells enriched in their responsiveness against the autologous 
EBV+ LCL. Further, we directly examine killing of target cells, 
rather than only NK-specific outcomes such as degranulation 
and IFNγ production as indirect measures for effects on target 
cells. Thus, despite the fact that the frequency of “responding” NK 
cells, as defined by expression of IFNγ or CD107a, was similar in 
cocultures with autologous B cells and EBV+ autologous LCL, our 
data clearly demonstrate that there is enhanced killing of EBV+ 
LCL by autologous NK cells. These results are consistent with the 
idea that NK cells can serially kill multiple targets (40–42), and 
explain why it has been hard to detect specific targeting of EBV+ 
LCL in past studies. This small subset of “serial” killers will be dif-
ficult to identify from the non-specific activity noted in cultures. 
Thus, here, we have phenotypically identified the small frequency 
of NK cells that account for the specific targeting of LCL.
We demonstrate that NKG2A-expressing NK cells are 
enriched for activity against latent EBV-infected LCL, with a 
more granular definition of NKG2A+2B4+CD16−CD57−NKG
2C−NKG2D+ NK cells. Further, blocking experiments suggest 
that NKG2D may play a role in the recognition of autologous 
LCL, but likely other receptors are involved. The absence of 
CD57 expression and the presence of NKG2A expression 
suggests that these are relatively immature NK cells since 
terminally differentiated NK cells typically lose expression of 
NKG2A and gain expression of CD57 (21, 43). NKG2A+CD57− 
NK cells have also been identified as important during other 
stages of EBV infection and thus may be relevant in innate 
regulation of EBV throughout its life cycle. EBV-responsive NK 
cells from the peripheral blood during primary symptomatic 
EBV infection have been described as CD56dimKIR−NKG2A+ 
(7), while those persisting after acute EBV infection are 
CD56dimNKG2A+CD57+ (28). Within the tonsils, an IFNγhiCD
56brightNKG2A+CD94+CD54+CD62L− NK cell subset has been 
implicated as the EBV-responsive NK cell that restricts primary 
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B cell infection (27). In fact, the age-related decline in immature 
NK cells (CD56dimNKG2A+NKR−NKG2C−CD57−), which make 
up the predominant subset in newborn infants and humanized 
mice, may reduce NK control of EBV infection and predispose 
adolescents for EBV+ IM (44). Thus, multiple lines of evidence 
suggest that NKG2A+CD57− NK cells play a critical role in con-
trolling EBV infection. It will, therefore, be of interest to study 
if the relative abundance of NKG2A+CD57− NK cells predicts 
susceptibility to EBV-LPD or EBV+ IM, or if these subsets can be 
expanded in vivo or ex vivo and used therapeutically.
Common among all studies of the NK cell response to EBV 
is the involvement of NKG2A, an NK inhibitory receptor, as a 
marker of EBV-responsive NK cells. The role of the inhibitory 
receptor NKG2A in NK cell responses to EBV remains unclear. 
NKG2A+ NK cells are also enriched in the ability to respond 
to HIV (45). This observation is explained by the presenta-
tion of a conserved HIV peptide by HLA-E that abrogates the 
interaction between NKG2A and HLA-E, resulting in the loss 
of this inhibitory signal and sensitization to killing by NKG2A+ 
NK cells (45). A similar mechanism could play a role in EBV, 
particularly since HLA-E is not downregulated by either HIV 
or EBV (46). It will be of interest to determine if EBV similarly 
expresses a conserved peptide that allows escape from NK 
cell inhibition mediated by the interaction of NKG2A and 
HLA-E. Alternately, it is possible that NKG2A is a marker of 
the EBV-responsive NK cell population but plays no direct 
role in NK cell function against EBV-infected cells. Most 
NKG2A-expressing NK cells do not co-express KIR (47–49), 
so these data could suggest that the absence of the inhibitory 
KIR receptors may allow this subset to be more activate against 
autologous LCL. Similarly, our data suggest that NGK2D may 
play a role in recognition of autologous LCL, since blocking 
NKG2D reduces NK cell IFNγ secretion by approximately 30%, 
strongly suggesting that multiple receptors are involved in the 
recognition of autologous LCL.
Our data suggest that the response to latent EBV infection 
may result from a shift in the balance from NK inhibition toward 
NK activation. Specifically, we observed reduced expression of 
the NK inhibitory ligands MHC class I and increased expression 
of the NK-activating ligand CD48 on EBV+ LCLs compared to 
host B cells. While Azzi et al. (7) reported an increase in MHC 
class I expression on autologous LCLs compared to CD19+ B 
cells from PBMCs, it is unclear if they accounted for differences 
in autofluorescence between the two cell types. In accord with 
our results, LCLs generated from an EBV strain lacking the 
latent protein LMP2a display increased MHC class I expres-
sion, suggesting that latent viral genes can downregulate MHC 
class I expression (50). Along similar lines, the downregulation 
of inhibitory ligands and an upregulation of activating ligands 
are thought to contribute to the NK response toward lytic EBV. 
In fact, the further downregulation of MHC class I during lytic 
infection and the upregulation of additional activating ligands, 
including CD112, ULBP1, MICA, and CD155 (6, 7), may 
help explain the difference in magnitude of the NK response 
to lytically versus latently EBV-infected B  cells. Ultimately, all 
NK studies are limited by our knowledge of verified ligands for 
NK cell receptors. Further studies enumerating the differential 
regulation of NK ligand expression between lytic and latent EBV 
infection in B cells may provide additional mechanistic insight 
into NK cell control of EBV infection.
Our results provide the first clear demonstration of a significant 
NK cell response to autologous EBV+ LCL as a model of latent 
EBV infection. These data help to complete our understanding 
of the role of NK cells throughout the EBV life cycle and may lay 
the groundwork for developing novel NK-based therapeutics for 
EBV-LPD.
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